TSX:BLU (Bellus Health)
About BLU
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Bellus Health (TSX: BLU) Latest News

Investing
Warren Buffett Is Betting Big on Drug Stocks

Investing
2 Top Oversold Stocks in the Coronavirus Market Crash

Metals and Mining Stocks
Canada Revenue Agency: 1 Major TFSA Mistake Could Cost You Thousands

Investing
This Little-Known Stock Increased Over 100% in 2019!

Investing
This Biotech Stock Is Set to Climb 500%

Investing
Trudeau’s Drug Price Overhaul Threatens This Company

Investing
The 3 Best Stocks of Summer 2019

Investing
TFSA Investors: Learn From the 3 Best-Performing Stocks of 2019

Metals and Mining Stocks
3 White-Hot Stocks to Buy This Instant

Energy Stocks
$7-and-Under Bargain Stocks to Buy Today

Investing
Top 2 TSX Healthcare Stocks to Buy in June
